期刊文献+

癌性疼痛患者从吗啡向芬太尼持续注入转换的换算比例研究 被引量:5

Equipotent ratio for conversion of morphine to continuous infusion of fentanyl in patients with cancer pain
下载PDF
导出
摘要 目的:探讨从吗啡向芬太尼持续注入转换的适当换算比例。方法:通过20例癌性疼痛患者的回顾性临床调查,对疼痛程度、药物不良反应及治疗满意度进行评价。结果:本组转换后1周内稳定(转换前后疼痛强度无明显变化)(Good组)的有17例,不稳定(Poor组)的有3例。芬太尼注射剂和吗啡有同等的镇痛效果;转换后能够减轻副作用、提高满意度。结论:推荐从低剂量吗啡向芬太尼注射剂转换的换算比例是72∶1,并且推测从非低用量吗啡向芬太尼注射剂转换的换算比例小于72∶1有可能达到稳定。但不可能确定从吗啡向芬太尼持续注入转换的具体换算比例,应考虑转换前吗啡用量,再行确定转换的具体比例。 Objective: To investigate the proper equipotent ratio for conversion of morphine to continuous infusion of fentanyl in patients who suffer from cancer pain. Methods: A retrospective study was performed on 20 patients with cancer pain in Shizuoka Cancer Center from 2002 Sep to 2003 Nov. Pain intensity, adverse reaction, and satisfaction index of patients were evaluated. Results:The pain intensity was stable before and after conversion in 17 patients within 1 week after conversion indicating good pain-control. It was unstable in 3 patients after conversion suggesting poor pain-control. Fentanyl injection had equipotent pain- relieving effects with morphine. Conversion of morphine to fentanyl injection could alleviate side effects and increase the satisfaction index of patients. Conclusions: An equipotent ratio for conversion of low dose morphine to fentanyl injection was established as 72 : 1, and for non low dose morphine a ratio less than 72 : 1 was proposed to get stable pain-relieving effect. But the equipotent ratio for conversion of morphine to continuous perfusion of fentanyl could not be determined. We must consider the morphine dosage before confirmation of the equipotent ratio.
出处 《肿瘤》 CAS CSCD 北大核心 2006年第11期1024-1027,共4页 Tumor
基金 日本笹川医学奖学金
关键词 肿瘤 疼痛 吗啡 芬太尼/投药和剂量 Neoplasms Pain Morphine Fentanyl/administration and dosage
  • 相关文献

参考文献15

  • 1PAIX A,COLEMAN A,LEES J,et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management[J]. Pain, 1995,63(2) : 263-269.
  • 2細井順,恒藤曉,池永昌之,ほか.フェンタニルの持続皮下注入にょるがん性疼痛の治療[J].死の临床,1997,20(1):64—67.
  • 3末永和之,為近義夫.癌性疼痛フェンタニルの有用性にっぃて[J].日本医事新報,1999,3914(5):42-47.
  • 4酒井一介,井手留美子,原克己.モルヒネ不耐性症例に对するフェンタニルの持统注入の检讨[J].佐世保市立總合病院纪要,2001,27:56.
  • 5池永昌之.新しぃォどォィド製剤発壳間近となってぃるものを含めた新しぃォビォィドフェンタニルの注射藥のがん性疼痛治療における有用性と問题点[J].缓和医療学,2002,4(2):99-104.
  • 6HOLMES CM. Supplementation of general anaesthesia with narcotic analgesies[J]. Br J Anaesth , 1976 ,48(9) :907-913.
  • 7KAY B, ROLLY G. Duration of action of analgesic supplements to anesthesia. A double blind comparison between morphine, fentanyl and sulfentanil[J]. Acta Anaesthesiol Belg,1977,28(1):25-32.
  • 8恒藤曉,他.フェンタニルの持统皮下注入にょる癌性疼痛の治療[J].ベィンクリニック,1994,15(1):63—66.
  • 9WATANABE S, PEREIRA J, HANSON J ,et al. Fentanyl by continuous subcutaneous infusion for the management of cancer pairl:a retrospective study[J]. J Pain Symptom Manage,1998,16(5) :323-326.
  • 10SINGER M, NOONAN KR. Continuous intravenous infusionof fentanyl:case reports of use in patients with advanced cancer and intractable pain[J]. J Pain Symptom Manage, 1993,8(4):215-220.

同被引文献40

引证文献5

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部